Revenue Growth
Q1 sales of $139 million, up 11% year-over-year and up 1% sequentially; diversified end markets sales up 18% and transportation sales up 3%.
Medical Market Outperformance
Medical sales of $25 million, up 28% YoY; medical bookings up 18% with a medical book-to-bill of 1.2; company expects continued double-digit medical sales growth and expanded capacity for therapeutic and aesthetics applications.
Industrial Momentum
Industrial sales of $37 million, up 14% YoY; industrial bookings up 28% and book-to-bill of 1.29 (vs 1.15 in 2025), driven by OEM and distribution recovery and wins across printing, flow meters, and temperature sensing.
Transportation Stability and Wins
Transportation sales of $60 million, up 3% YoY and 7% sequentially; multiple new business awards including current sensing and foot controls (Europe) and an accelerometer award (North American OEM); strengthening footwell and sensor portfolio.
Gross Margin Expansion
Adjusted gross margin of 39.5%, an improvement of 250 basis points YoY and +40 basis points sequentially, driven by operational improvements and favorable end-market mix.
Profitability Improvement
Adjusted diluted EPS of $0.62 in Q1 versus $0.44 prior year, an increase of ~41%; GAAP diluted EPS $0.59 versus $0.44 (~34% increase).
Strong Bookings and Backlog
Company-wide book-to-bill of 1.1 (up 4% vs 2025) and total booked business of approximately $1.1 billion at quarter end; strong bookings momentum in industrial and medical markets.
Large Defense Opportunity Win
Awarded a significant underwater hull penetrator win with a potential contract value of ~$20 million over five years and multiple naval sonar/filter wins; two new RF filter customers added.
Cash Generation and Capital Returns
Operating cash flow of $17 million YTD; cash balance $91 million; borrowings $63 million; returned $10 million to shareholders (dividends + buybacks) and repurchased ~177,000 shares (~$9 million); $82 million remaining on repurchase authorization.
Narrowed Full-Year Guidance
Full-year 2026 sales guidance narrowed to $560M–$580M and adjusted diluted EPS guidance narrowed to $2.35–$2.45, reflecting confidence in outlook assuming market continuity.